mRNA vaccine responses in PLWH

NIH Pandemic-Era Grants

Pandemic Era Grants

2023

↗ Live URL (may be dead)

Document text

Principal Investigator: JOEL N BLANKSON
Organization: JOHNS HOPKINS UNIVERSITY
Fiscal Year: 2023
Award: $204,688
Funding agency: National Institute of Allergy and Infectious Diseases

Project Summary
Two mRNA COVID vaccines that have greater than 90% efficacy in healthy donors have
been developed. However the efficacy of these vaccines in PLWH is unknown. PLWH
have had suboptimal responses to some prior vaccines potentially because they make
limited naïve T cell responses. We and others have shown T cell cross-recognition of
spike proteins from SARS-CoV-2 and the common cold coronavirus and demonstrated
that these cross-reactive responses are less effective against SARS-CoV-2 than mono-
reactive responses. We hypothesize that cross-reactive memory responses will
contribute more towards the total SARS-CoV-2 responses in PLWH than in healthy
donors and this will result in less effective responses to the mRNA vaccines. We will test
this hypothesis by comparing CD4+ T cell and antibody responses in vaccinated healthy
donors and PLWH. Our results will have major implications for future policies regarding
booster shots for PLWH and the general population

Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV S protein><2019-nCoV spike glycoprotein><2019-nCoV spike protein><Acute Nasopharyngitis><Affinity><Antibodies><Antibody Response><Antibody titer measurement><Antigens><Avidity><B.1.1.7><Binding><CD4 Cells><CD4 Positive T Lymphocytes><CD4 T cells><CD4 helper T cell><CD4 lymphocyte><CD4+ T-Lymphocyte><CD4-Positive Lymphocytes><COVID><COVID-19><COVID-19 S protein><COVID-19 antibody><COVID-19 antigen><COVID-19 immunity><COVID-19 spike glycoprotein><COVID-19 spike protein><COVID-19 vaccination><COVID-19 virus><COVID19><COVID19 S protein><COVID19 immunity><COVID19 spike glycoprotein><COVID19 spike protein><COVID19 vaccination><COVID19 virus><CV-19><CV19><Clonal Expansion><CoV disease><CoV-2><CoV2><Coin><Common Cold><Coronaviridae><Coronaviridae Infections><Coronavirus><Coronavirus Infections><Data><Development><Future><General Population><General Public><H1N1><H1N1 Virus><HCoV><Immunization><Immunize><Individual><Infection><Influenza A Virus, H1N1 Subtype><Lymphatic cell><Lymphocyte><Lymphocytic><Memory><Memory B Cell><Memory B-Lymphocyte><Messenger RNA><Molecular Interaction><Outcome><Patients><Peptides><Policies><RNA immunization><RNA vaccination><RNA vaccine><RNA-based vaccine><Receptor Protein><Respiratory Disease><Respiratory System Disease><Respiratory System Disorder><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 B.1.1.7><SARS-CoV-2 S protein><SARS-CoV-2 alpha><SARS-CoV-2 antibody><SARS-CoV-2 antigen><SARS-CoV-2 immunity><SARS-CoV-2 spike glycoprotein><SARS-CoV-2 spike protein><SARS-CoV-2 vaccination><SARS-CoV2><SARS-CoV2 S protein><SARS-CoV2 antibody><SARS-CoV2 antigen><SARS-CoV2 spike glycoprotein><SARS-CoV2 spike protein><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 S protein><Severe acute respiratory syndrome coronavirus 2 immunity><Severe acute respiratory syndrome coronavirus 2 spike glycoprotein><Severe acute respiratory syndrome coronavirus 2 spike protein><Severe acute respiratory syndrome coronavirus 2 vaccination><Severe acute respiratory syndrome related corona virus 2><T cell response><T memory cell><T-Cells><T-Lymphocyte><T-cell receptor repertoire><T4 Cells><T4 Lymphocytes><TCR repertoire><Testing><U.K. variant><UK strain><UK variant><United Kingdom variant><Upper Respiratory Infections><Upper Respiratory Tract Infection><Vaccinated><Vaccination><Vaccines><Variant><Variation><Virus><Wuhan coronavirus><antibody against COVID-19><antibody against SARS-CoV-2><antibody against SARS-CoV2><antibody against coronavirus disease 2019><antibody against severe acute respiratory syndrome coronavirus 2><antibody titering><antibody to COVID-19><antibody to SARS-CoV-2><antibody to SARS-CoV2><antibody to coronavirus disease 2019><antibody to severe acute respiratory syndrome coronavirus 2><booster dose><booster shot><booster vaccine><corona virus><corona virus disease><corona virus disease 2019><coronavirus disease><coronavirus disease 2019><coronavirus disease 2019 S protein><coronavirus disease 2019 antibody><coronavirus disease 2019 antigen><coronavirus disease 2019 immunity><coronavirus disease 2019 spike glycoprotein><coronavirus disease 2019 spike protein><coronavirus disease 2019 vaccination><coronavirus disease 2019 virus><coronavirus disease-19><coronavirus disease-19 virus><coronavirus infectious disease-19><cross reactivity><determine efficacy><developmental><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><evaluate efficacy><examine efficacy><flu serotype><flu strain><flu subtype><flu viral strain><flu virus strain><hCoV19><human CoV><human corona virus><human coronavirus><immunity against COVID-19><immunity against COVID19><immunity against SARS-CoV-2><immunity against Severe acute respiratory syndrome coronavirus 2><immunity against coronavirus disease 2019><immunity to COVID-19><immunity to COVID19><immunity to SARS-CoV-2><immunity to Severe acute respiratory syndrome coronavirus 2><immunity to coronavirus disease 2019><immunogen><influenza serotype><influenza strain><influenza subtype><influenza viral strain><influenza virus strain><lymph cell><mRNA><mRNA immunization><mRNA vaccination><mRNA vaccine><mRNA-based vaccine><memory T lymphocyte><mortality><nCoV2><pathogen><phrases><receptor><response><seroconversion><severe acute respiratory syndrome coronavirus 2 B.1.1.7><severe acute respiratory syndrome coronavirus 2 antibody><severe acute respiratory syndrome coronavirus 2 antigen><thymus derived lymphocyte><vaccinate against COVID-19><vaccinate against COVID19><vaccinate against SARS-CoV-2><vaccinate against coronavirus disease 2019><vaccinate against severe acute respiratory syndrome coronavirus 2><vaccination against COVID-19><vaccination against COVID19><vaccination against SARS-CoV-2><vaccination against Severe acute respiratory syndrome coronavirus 2><vaccination against coronavirus disease 2019><vaccine efficacy><vaccine response><vaccine responsiveness><vaccine-induced response><variants of concern>